- Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
-
Kim J
- KMID: 2395802
- Int J Arrhythm.
- 2017 Sep;18(3):148-150.
- doi: 10.18501/arrhythmia.2017.024
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Dabigatran approaching the realm of heparin-induced thrombocytopenia
-
Ho PJ, Siordia JA
- KMID: 2309208
- Blood Res.
- 2016 Jun;51(2):77-87.
- doi: 10.5045/br.2016.51.2.77
Heparin-induced thrombocytopenia (HIT) is a serious, immune mediated complication of exposure to unfractionated or low-molecular-weight heparin. Though rare, it is a condition associated with high morbidity and mortality that requires... -
- CITED
-
- Close
- SHARE
-
- Close
- Hemopericardium and Cardiac Tamponade in a Patient Treated with Dabigatran Etexilate
-
Kizilirmak F, Gunes HM, Guler E, Demir GG, Karaca O, Canpolat H
- KMID: 2223775
- Korean Circ J.
- 2016 Jan;46(1):99-101.
- doi: 10.4070/kcj.2016.46.1.99
Dabigatran etexilate is one of the new oral anticoagulants approved to reduce the risk of stroke in patients with atrial fibrillation (AF). A variety of bleeding complications with dabigatran have... -
- CITED
-
- Close
- SHARE
-
- Close
- Dabigatran Effect on Left Ventricular Thrombus in a Patient with Acute Ischemic Stroke
-
Chung K, Paek YM, Lee HJ, Hong KS
- KMID: 2381502
- J Stroke.
- 2015 Sep;17(3):366-368.
- doi: 10.5853/jos.2015.17.3.366
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Gastrointestinal Bleeding with Dabigatran, a Comparative Study with Warfarin: A Multicenter Experience
-
Sherid M, Sifuentes , Sulaiman S, Samo S, Husein H, Tupper R, Spurr C, Sridhar S
- KMID: 2373211
- Korean J Gastroenterol.
- 2015 Apr;65(4):205-214.
- doi: 10.4166/kjg.2015.65.4.205
BACKGROUND/AIMS: The risk of gastrointestinal (GI) bleeding with dabigatran when compared to warfarin has been controversial in the literature. The aim of our study was to assess this risk with... -
- CITED
-
- Close
- SHARE
-
- Close
- Practice Preferences on Dabigatran and Rivaroxaban for Stroke Prevention in Patients with Non-valvular Atrial Fibrillation
-
Park YK, Kang JE, Kim SJ, La HO, Rhie SJ
- KMID: 2358236
- Korean J Clin Pharm.
- 2016 Sep;26(3):207-212.
- doi: 10.0000/kjcp.2016.26.3.207
OBJECTIVE: Prescription rate of dabigatran and rivaroxaban, which are the direct oral anticoagulants (DOAC), has increased. We have analyzed the prescription trend and medication use of dabigatran and rivaroxaban in... -
- CITED
-
- Close
- SHARE
-
- Close
- The Need for a Coagulation Assay after Initiation of New Oral Anticoagulants in Patients with Renal Dysfunction: A Case Report
-
Lee MJ, Jang HM, Jeong WK, Bang OY
- KMID: 2179761
- J Clin Neurol.
- 2015 Oct;11(4):395-397.
- doi: 10.3988/jcn.2015.11.4.395
BACKGROUND: Dabigatran etexilate, a new oral anticoagulant, was recently approved as an efficacious alternative to warfarin for the prevention of first and recurrent stroke in patients with nonvalvular atrial fibrillation.... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-Term Anticoagulation in the Extreme Elderly with the Newer Antithrombotics: Safe or Sorry?
-
Chiong JR, Cheung RJ
- KMID: 2224916
- Korean Circ J.
- 2013 May;43(5):287-292.
- doi: 10.4070/kcj.2013.43.5.287
BACKGROUND AND OBJECTIVES: The prevalence of atrial fibrillation (AF) doubles in the extreme elderly and is higher than in the rest of the population. Warfarin therapy to prevent thromboembolic events... -
- CITED
-
- Close
- SHARE
-
- Close
- Use of NOAC in Cardioversion
-
Kim JB
- KMID: 2308908
- Int J Arrhythm.
- 2016 Mar;17(1):46-50.
- doi: 10.18501/arrhythmia.2016.007
Cardioversion increases the risk for stroke or systemic embolic events, and patients scheduled for cardioversions need several weeks of anticoagulant treatment to prevent these adverse events. Anticoagulant therapy should be... -
- CITED
-
- Close
- SHARE
-
- Close
- Risk Factors of Gastrointestinal Bleeding in Patients Receiving New Oral Anticoagulants
-
Lee JY
- KMID: 2428008
- Korean J Helicobacter Up Gastrointest Res.
- 2018 Dec;18(4):219-224.
- doi: 10.7704/kjhugr.2018.18.4.219
New oral anticoagulants (NOACs) are now widely used for the prevention and treatment of venous thrombosis, and for the prevention of stroke and systemic embolism in patients with atrial fibrillation.... -
- CITED
-
- Close
- SHARE
-
- Close
- Application of New Oral Anticoagulants: Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation
-
Kim D, Lee MY
- KMID: 2269259
- Korean J Med.
- 2014 Jul;87(1):26-33.
Only anticoagulation has been shown to reduce atrial fibrillation-related deaths. Vitamin K antagonists are difficult to use due to their narrow therapeutic range, unpredictable response, requirement for frequent coagulation monitoring,... -
- CITED
-
- Close
- SHARE
-
- Close
- Dabigatran Toxicity Secondary to Acute Kidney Injury
-
Moon HH, Lee SE, Oh DJ, Jo HB, Kwon KH, Kim YJ, Kim KS, Shin SJ
- KMID: 2203554
- J Korean Soc Clin Toxicol.
- 2014 Dec;12(2):92-96.
Dabigatran is the first oral direct thrombin inhibitor approved by the US Food and Drug Administration (FDA) for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.... -
- CITED
-
- Close
- SHARE
-
- Close
- New Oral Anticoagulants: General Features and Review of Pivotal Clinical Trials
-
Jang SW
- KMID: 2383556
- Korean J Helicobacter Up Gastrointest Res.
- 2016 Dec;16(4):178-184.
- doi: 10.7704/kjhugr.2016.16.4.178
For the last half century, vitamin K antagonists (VKAs) have been used for treatment and prevention of venous thromboembolism and stroke prevention in patients with atrial fibrillation. However, their fragile... -
- CITED
-
- Close
- SHARE
-
- Close
- Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other Populations
-
Toyoda K, Yamagami H, Koga M
- KMID: 2428767
- J Stroke.
- 2018 Sep;20(3):321-331.
- doi: 10.5853/jos.2018.01788
Development of direct oral anticoagulants and their antidotes has led to the need to reconsider the eligibility of acute stroke patients who have been taking oral anticoagulants for intravenous thrombolysis.... -
- CITED
-
- Close
- SHARE
-
- Close
- Non-Vitamin K Oral Anticoagulants Associated Bleeding and Its Antidotes
-
Steiner T, Köhrmann , Schellinger PD, Tsivgoulis G
- KMID: 2428765
- J Stroke.
- 2018 Sep;20(3):292-301.
- doi: 10.5853/jos.2018.02250
Oral anticoagulant-associated intracerebral hemorrhage (OAC-ICH) accounts for nearly 20% of all ICH. The number of patients with an indication for oral anticoagulant therapy (OAT) increases with increasing age. OAT became... -
- CITED
-
- Close
- SHARE
-
- Close
- New oral anticoagulants
-
Oh S
- KMID: 2192901
- J Korean Med Assoc.
- 2013 Jan;56(1):57-61.
- doi: 10.5124/jkma.2013.56.1.57
The most important and widely-prescribed drug for anticoagulation is a vitamin K antagonist such as warfarin although it has several limitations in clinical use. New oral anticoagulants (NOACs) have been... -
- CITED
-
- Close
- SHARE
-
- Close
- Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients
-
Joung B
- KMID: 2396475
- Korean Circ J.
- 2017 Nov;47(6):833-841.
- doi: 10.4070/kcj.2017.0158
Regulatory approvals of non-vitamin K antagonist oral anticoagulants (NOACs) have been based on large randomized phase III trials evaluating dabigatran, rivaroxaban, apixaban, or edoxaban relative to warfarin for atrial fibrillation... -
- CITED
-
- Close
- SHARE
-
- Close
- Acute kidney injury aggravated by treatment initiation with apixaban: Another twist of anticoagulant-related nephropathy
-
Brodsky SV, Mhaskar NS, Thiruveedi S, Dhingra R, Reuben SC, Calomeni E, Ivanov I, Satoskar A, Hemminger , Nadasdy G, Hebert L, Rovin B, Nadasdy T
- KMID: 2405114
- Kidney Res Clin Pract.
- 2017 Dec;36(4):387-392.
- doi: 10.23876/j.krcp.2017.36.4.387
Anticoagulant-related nephropathy (ARN) was initially described in patients on warfarin (as warfarin-related nephropathy) and recently in those using dabigatran. Herein, we report clinical history and kidney biopsy findings in a... -
- CITED
-
- Close
- SHARE
-
- Close
- Non-Vitamin K Antagonist Oral Anticoagulants in Medical Conditions at High Risk of Thromboembolism beyond Atrial Fibrillation
-
Hong KS
- KMID: 2464644
- J Stroke.
- 2019 Sep;21(3):259-275.
- doi: 10.5853/jos.2019.01970
Non-Vitamin K antagonist oral anticoagulants (NOACs) have been extensively investigated in medical conditions at high risk of venous or arterial thrombosis other than atrial fibrillation (AF), including hip or knee... -
- CITED
-
- Close
- SHARE
-
- Close
- Focused Update of Guidelines for Antithrombotic Management of Patients with Atrial Fibrillation and Ischemic Stroke or Transient Ischemic Attack
-
Jung KH, Yu KH, Kim YD, Park JM, Hong KS, Rha JH, Kwon SU, Bae HJ, Heo JH, Lee BC, Yoon BW
- KMID: 2345240
- J Korean Neurol Assoc.
- 2016 Aug;34(3):184-192.
- doi: 10.17340/jkna.2016.3.3
Cardioembolic stroke related to atrial fibrillation is problematic due to high recurrence, mortality, and morbidity rates. The optimal anticoagulant therapy therefore needs to be applied to prevent the occurrence of... -
- CITED
-
- Close
- SHARE
-
- Close
